2019 American Transplant Congress
Evaluation of Mycophenolate Mofetil Exposure in Renal Transplant Recipients
*Purpose: Mycophenolate mofetil (MMF) is the most commonly prescribed immunosuppressant following transplantation in the United States. However, the occurrence of MMF therapy-related adverse events including…2019 American Transplant Congress
Retrospective Nested Case Control Study of the Impact of Immunosuppression on Post Transplant Malignancy among Adult Heart Transplant Patients
*Purpose: Post-transplant malignancy is diagnosed in approximately 18% of heart transplant (HTx) recipients and is a leading long-term cause of death among these patients. The…2019 American Transplant Congress
Development and Validation of a Capillary Blood Mitra-Based Assay for the Quantitative Determination of Advagraf® Concentrations in Transplant Patients
*Purpose: Therapeutic drug monitoring of tacrolimus (TAC) requires venepuncture blood samples taken by specialists, requiring patients to attend an outpatient clinic; this can be inconvenient…2019 American Transplant Congress
The Comparative Safety and Efficacy of Direct Acting Oral Anticoagulants Relative to Warfarin Following Liver Transplantation
Mount Sinai Hospital, New York, NY
*Purpose: This study describes the comparative safety and efficacy of direct acting oral anticoagulants (DOACs) relative to warfarin following liver transplantation, at a large academic…2019 American Transplant Congress
Impact of Liver Recipient Genotype on Tacrolimus
*Purpose: In kidney transplant recipients, recipient genotype (CYP3A5 *3) has the greatest influence on tacrolimus pharmacokinetics (PK). However, in liver transplant recipient, donor liver and…2019 American Transplant Congress
A Clinical Pharmacogenetic Model to Predict the Efficacy of Sirolimus during the Early Administration in Renal Transplant Recipients
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: This study was to develop a clinical pharmacogenetic model to predict the efficacy of sirolimus during the early administration in renal transplant recipients. 70…2019 American Transplant Congress
Association of Tacrolimus-Level Variance with De Novo DSA within the First 2 Years after Renal Transplantation
*Purpose: Patients that receive an HLA-mismatched kidney transplant (KT) have an increased likelihood to develop de novo DSA (dnDSA). Ideally, immunosuppression is properly adjusted and…2019 American Transplant Congress
Intravenous Immunoglobulin Significantly Reduces Bioavailability of Concomitantly Administered Anti-C5 Monoclonal Antibodies
*Purpose: Awareness of drug-drug interactions is critical in management of organ transplant recipients. However, there is little understanding of the possibility of biologic agents interfering…2019 American Transplant Congress
Tacrolimus Concentration/Dose Ratio is an Independent Predictor of Death-Censored Kidney Allograft Survival
*Purpose: Tacrolimus (Tac) remains the cornerstone of kidney transplantation immunosuppression. Its narrow therapeutic index demands therapeutic drug monitoring. The C/D ratio (Tac trough concentration /…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »